The Need for a Consensus
CTMS cloud application streamlines trial management and delivers end-to-end visibility of clinical trials on one platform
ZERVIATE was established in three randomized, double-masked, placebo-controlled, conjunctival antigen challenge (Ora-CAC®3 model of allergic conjunctivitis)
Ophthalmic Product Development Insights
Digging deeper into the types of patients who get dry eye and the situations that can bring it on.
Allergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimulating Device Proven to Temporarily Increase Tear Production
AXIM Biotech Retains Ora to Manage Upcoming Product Development and Clinical Trials on Glaucoma and Dry Eye Indications
Results of the first phase 3 trial in this field were announced.
Okogen Secures Ora to Conduct Clinical and Regulatory Development of OKG-0301 for Adenoviral Conjunctivitis
Okogen, Inc. to present at 2017 Biotech Showcase